ThromboGenics' Founder Prof Desire Collen Retiring as Chairman

        ThromboGenics' Founder Prof Desire Collen Retiring as Chairman

  PR Newswire

  LEUVEN, Belgium, December 6, 2013

LEUVEN, Belgium, December 6, 2013 /PRNewswire/ --

Dr Staf Van Reet appointed as new Chairman of the Board

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical
company focused on developing and commercializing innovative ophthalmic
medicines, announces today that Prof Désiré Collen has decided to retire as
Chairman and board member. Dr Staf Van Reet, currently a member of the
ThromboGenics Board and a seasoned biopharma veteran, has been appointed
Chairman of ThromboGenics.

Prof Collen, Founder and Chairman of ThromboGenics, said : " As the founder
and a key member of the ThromboGenics team for more than 20 years, I ' ve
decided it is time for me to take a step back and to stand down from my
current role as ThromboGenics '  Chairman. I believe that this is an
appropriate time to hand over to my successor.

" Recognizing a number of challenges, I believe that the Company has a clear
strategy to optimize the  US  sales of JETREA ^® and in the rest of the
world via its partner Alcon. I remain confident that JETREA ^® will find its
way forward as part of a new standard of care for the treatment of symptomatic
VMA/VMT, particularly for earlier stage patients. "    

Prof Collen, a world renowned scientist, has played an instrumental role in
ThromboGenics' development and subsequent success since he founded the Company
in 1991. During his tenure as CEO of ThromboGenics, the company started its
research on JETREA ^® (ocriplasmin) and advanced it through its early clinical
development for the treatment of symptomatic vitreomacular adhesion (VMA)/
vitreomacular traction (VMT). He was appointed ThromboGenics' Chairman at the
founding of the company.

Prof Collen has had an extensive and prominent career in drug development.
Before the successful development of JETREA ^® , Prof Collen led the research
and development of tissue plasminogen activator (tPA), a key product for
Genentech in the late 1980s and 1990s. This product revolutionized the
treatment of acute myocardial infarction and stroke when it was introduced.

Prof Collen has been recognized as a leading figure in the life sciences
industry. He has won numerous awards, including two recent lifetime
achievement awards as recognition of his excellent services to the global
industry. He has co-authored more than 650 scientific publications, and has
co-invented over 20 issued patents and patent applications. During his career,
he has proved a successful biotech entrepreneur and investor. In 1998 he set
up Life Sciences Research Partners, which invests in emerging life sciences
companies and promotes scientific research through grants, scholarships and
related activities.

ThromboGenics has appointed Dr Staf Van Reet, currently on the ThromboGenics
Board of Directors, as the company's new Chairman.

Dr Van Reet was previously Head of R&D at Janssen Pharmaceuticals, and was
co-founder of Movetis N.V. and Chairman of its Board of Directors until
November 2010, when the company was acquired by Shire S.a.r.l. Currently, he
is Chairman of the Board of Directors of Actogenix N.V. and Okapi Sciences
N.V. and a director of Biocartis S.A., Therasolve N.V. and VIB (the Flemish
Institute of Biotechnology).

Dr Staf Van Reet said : " Desiré has made a huge contribution to the growth of
ThromboGenics and the successful development of JETREA ^® . On behalf of the
entire ThromboGenics team, I am extremely grateful for his dedication and
commitment to the Company, which is now a leader in the European biotech
industry. I look forward to continuing his record and to ensure the successful
growth trajectory of JETREA ^® and further development of ThromboGenics ' 
emerging portfolio of therapies for the treatment of diabetes-related retinal
diseases. " 

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The
Company's lead product, JETREA ^® (ocriplasmin), has been approved by the US
FDA for the treatment of symptomatic VMA and was launched in January 2013. 

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the
commercialization of JETREA ^® outside the United States. Under this
agreement, ThromboGenics could receive up to a total of €375 million in
up-front and milestone payments. It will receive significant royalties from
Alcon's net sales of JETREA ^® . ThromboGenics and Alcon intend to share the
costs equally of developing JETREA ^® for a number of new vitreoretinal
indications.

In Europe, JETREA ^® is approved for the treatment of vitreomacular traction
(VMT), including when associated with macular hole of diameter less than or
equal to 400 microns. Alcon has launched JETREA ^® in the UK, Germany,
Finland, Denmark, Norway, Sweden and Canada. 

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor),
also referred to as TB-403, for the treatment of ophthalmic and oncology
indications.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available at
http://www.thrombogenics.com .

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained
in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction.  No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

For further information please contact: Thrombogenics Wouter Piepers, Global
Head of Corporate Communications +32-16-75-13-10 / +32-478-33-56-32
wouter.piepers@thrombogenics.com Dr. Patrik De Haes, CEO +32-16-75-13-10
Patrik.dehaes@thrombogenics.com Chris Buyse, CFO +32-16-75-13-10
Chris.buyse@thrombogenics.com Citigate Dewe Rogerson David Dible/ Sita Shah
Tel: +44-20-7638-9571  sita.shah@citigatedr.co.uk The Trout Group (US
investor relations) Todd James/ Simon Harnest Tel: +1-646-378-2926
tjames@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.